Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events. Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency. The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2. Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported. Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis. From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0.9% [95% confidence interval (CI): 0.3–2.4], a hospitalization rate of 100% and a mortality rate of 77.8%. Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1.5% (95% CI: 0.5–3.1), with 100% hospitalization and 64% mortality. The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated (p = 0.009, p < 0.0001, p < 0.0001). Overall COVID-19 prevalence was 1.2% for vaccinated (six of 482 cases, all confirmed) and 1.7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0.52. The difference remained non-significant, considering confirmed COVID-19 only (p = 0.33). Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases. Influenza vaccination does not protect from SARS-CoV-2 infection.

[1]  A. Hauschild,et al.  Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI) , 2020 .

[2]  G. Tortora,et al.  Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment , 2020, Journal for ImmunoTherapy of Cancer.

[3]  J. Becker,et al.  On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19 , 2020, Journal for ImmunoTherapy of Cancer.

[4]  E. Tartour,et al.  Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab , 2020, Cancer Immunology, Immunotherapy.

[5]  Chih-Jen Yang,et al.  Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic , 2020, Lung Cancer.

[6]  V. Torri,et al.  COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study , 2020, The Lancet Oncology.

[7]  A. Lazzarin,et al.  Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy , 2020, Clinical Immunology.

[8]  X. Chen,et al.  Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study , 2020, Clinical Microbiology and Infection.

[9]  Steven Woloshin,et al.  False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. , 2020, The New England journal of medicine.

[10]  Jun Yu Li,et al.  Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.

[11]  Alokkumar Jha,et al.  Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study , 2020, The Lancet.

[12]  P. Quaglino,et al.  Metastatic melanoma treatment with checkpoint inhibitors in the COVID‐19 era: experience from an Italian Skin Cancer Unit , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  J. Wolchok,et al.  Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers , 2020, Cancer discovery.

[14]  M. Rugge,et al.  Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) , 2020, Annals of Oncology.

[15]  M. Santillana,et al.  Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.

[16]  H. Miyashita,et al.  Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City , 2020, Annals of Oncology.

[17]  M. Chua,et al.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China , 2020, JAMA oncology.

[18]  M. Bersanelli,et al.  Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors , 2020, Immunotherapy.

[19]  J. Hageman.  The Coronavirus Disease 2019 (COVID-19). , 2020, Pediatric annals.

[20]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[21]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[22]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[23]  F. Mazzoni,et al.  Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. , 2020, Immunotherapy.

[24]  J. Wallinga,et al.  Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. , 2018, European journal of cancer.

[25]  F. Mazzoni,et al.  INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. , 2018, Immunotherapy.

[26]  C. Chung.  To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade , 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[27]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  T. Vuong,et al.  Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. , 2017, Critical reviews in oncology/hematology.

[29]  D. Eibach,et al.  Performance of influenza case definitions for influenza community surveillance: based on the French influenza surveillance network GROG, 2009-2014 , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[30]  S. Buti,et al.  From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis , 2017, World journal of clinical oncology.

[31]  Yi-Wei Tang,et al.  Rapid Molecular Detection and Differentiation of Influenza Viruses A and B. , 2017, Journal of visualized experiments : JoVE.

[32]  M. Burotto,et al.  Pseudoprogression and Immune-Related Response in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Baldanti,et al.  Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM) , 2014, Annals of Oncology.

[34]  A. Bousvaros,et al.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  N. Karim,et al.  Influenza vaccination in cancer patients undergoing systemic therapy. , 2014, Clinical Medicine Insights. Oncology.

[36]  C. Beck,et al.  Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. , 2012, Journal of Infectious Diseases.

[37]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[38]  S. Chasalow,et al.  Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.

[39]  M. Rota,et al.  Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2010-2011 , 2010 .

[40]  O. Lund,et al.  An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.

[41]  L. Elting,et al.  Epidemiology and outcomes of serious influenza‐related infections in the cancer population , 2005, Cancer.

[42]  David A Rand,et al.  Foreignness as a matter of degree: the relative immunogenicity of peptide/MHC ligands. , 2004, Journal of theoretical biology.

[43]  A. Charlett,et al.  Seroconversion after influenza vaccination in patients with lung cancer , 1999, British Journal of Cancer.

[44]  S. Kohno,et al.  The pattern of respiratory infection in patients with lung cancer. , 1994, The Tohoku journal of experimental medicine.

[45]  R. Rubin,et al.  Approach to immunization in the immunosuppressed host. , 1990, Infectious disease clinics of North America.

[46]  Lawrence Tagg.  Services , 1987, Veterinary Record.

[47]  JurgW. Tauber.  "SELF": STANDARD OF COMPARISON FOR IMMUNOLOGICAL RECOGNITION OF FOREIGNNESS , 1976, The Lancet.

[48]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[49]  P. Maurer.  Immunogenicity and the nature of antigens. , 1965, The Medical clinics of North America.

[50]  Chao Qian,et al.  Population , 1940, State Rankings 2020: A Statistical View of America.

[51]  J. Blay,et al.  Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City , 2020 .

[52]  Dmitrij Frishman,et al.  Assessment of cancer and virus antigens for cross-reactivity in human tissues , 2017, Bioinform..

[53]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[54]  Darja Kanduc,et al.  Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences. , 2008, Advances in experimental medicine and biology.

[55]  L. Brydak,et al.  Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. , 1999, Leukemia & lymphoma.